Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 15,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Product Clear all

Conditions: Emphysema
Interventions: Placebo, RAR Gamma; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 44 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more

Conditions: Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
Interventions: Ivonescimab, 5-Fluorouracil, Oxaliplatin, Leucovorin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Santa Monica, California • Boston, Massachusetts

Conditions: Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Childhood Fibrolamellar Carcinoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Fibrolamellar Carcinoma, Refractory Malignant Solid Neoplasm
Interventions: Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan; Biological · Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 39 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more

Conditions: Sarcoma, Refractory Sarcoma
Interventions: Pazopanib, Irinotecan, Temozolomide; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Oakland, California • San Francisco, California • Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: VNZ/TEZ/D-IVA, Rosuvastatin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Rheumatoid Arthritis
Interventions: FB704A, Placebo; Drug
Lead sponsor: Fountain Biopharma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: COVID-19
Interventions: COVID-HIGIV, Placebo (saline); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: TAK-788, Itraconazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Major Depressive Disorder
Interventions: (2R,6R)-Hydroxynorketamine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: NNC0662-0419, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Lancaster, California • Lomita, California • Long Beach, California + 20 more

Conditions: HIV Infections
Interventions: Interruption of enfuvirtide, enfuvirtide interrupton; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Muscle Invasive Bladder Cancer
Interventions: AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more

Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions: Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Cincinnati, Ohio

Conditions: Myocardial Infarction
Interventions: Clopidogrel; Drug
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 21 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Commack, New York • Harrison, New York • New York, New York + 5 more

Conditions: Bipolar Disorder
Interventions: Metformin, healthy lifestyle intervention (LIFE); Drug · Behavioral
Lead sponsor: Melissa Delbello; Other
Eligibility: 8 Years to 19 Years
Enrollment: 1,565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 29
States / cities: Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more

Conditions: Anemia of Chronic Kidney Disease
Interventions: Erythropoiesis-Stimulating Agent (ESA), Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 18
States / cities: Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more

Conditions: Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1, Glucagon
Interventions: GB, Placebo; Dietary Supplement
Lead sponsor: Lawry Han; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Osteoarthritis of the Knee, Coagulopathy
Interventions: Pennsaid; Drug
Lead sponsor: Nathan Wei, MD, FACP, FACR:; Other
Eligibility: 55 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Alcohol Dependence
Interventions: Zonisamide, Take Control, Placebo (for Zonisamide); Drug · Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 21 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infection
Interventions: Raltegravir; Drug
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Postpartum Period
Interventions: W-PPMA; Device
Lead sponsor: Woebot Health; Industry
Eligibility: 16 Years and older
Enrollment: 281 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
Interventions: Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Maynard, Massachusetts

Conditions: Smoking Cessation
Interventions: CQSS2, NicoDerm CQ Patch; Drug
Lead sponsor: Chrono Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 5
States / cities: Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 2 more

Search by objective public record fields.

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism

Pilot Study of Raltegravir Lipodystrophy IISP

W-PPMA for Postpartum Mothers

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Safety and Efficacy Study of the NRT CQSS2 System for Smoking Cessation in Treatment-Seeking Subjects